Medeon Biodesign, Inc.
6499
Rank in Stocks
#16276
Medeon Biodesign, Inc. engages in the research and development, manufacturing,... Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular graft system; PUMA, solution to treat orthopedic extremity injuries; ClickClean, a solution to view throughout laparoscopic surgeries; and AbClose to prevent port site herniation caused by improper closure. It is engaged in the medical device contract manufacturing; and manufacture and sale of injection molding and components of medical devices. Medeon Biodesign, Inc. was incorporated in 2012 and is based in Taipei, Taiwan.
Share Price
$2.25
Last synced: 2026-11-10
Market Cap
$218.10M
Change (1 day)
1.10%
Change (1 year)
-28.85%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Medeon Biodesign, Inc. (6499)
Category
Technology
Operating Margin for Medeon Biodesign, Inc. (6499)
Operating Margin as of November 2026 TTM: -144.72%
According to Medeon Biodesign, Inc.'s latest financial reports, its current operating margin (TTM) is -144.72%. At the end of 2025 the company had an operating margin of -172.26%.
Operating Margin history for Medeon Biodesign, Inc. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -144.72% | -15.99% |
| 2025 | -172.26% | -42.17% |
| 2024 | -297.87% | -30.32% |
| 2023 | -427.48% | 161.41% |
| 2022 | -163.53% | -78.01% |
| 2021 | -743.77% | 168.31% |
| 2020 | -277.21% | 401.65% |
| 2019 | -55.26% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 33.17% | -100.23% |
US
|
|
| 46.13% | -100.32% |
KR
|
|
| 13.29% | -100.09% |
JP
|
|
| 53.84% | -100.37% |
JP
|
|
| 6.07% | -100.04% |
CN
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Medeon Biodesign, Inc.'s operating margin
What is Medeon Biodesign, Inc.'s operating margin?
Medeon Biodesign, Inc.'s operating margin is -144.72%, as of Nov 2026.
What was Medeon Biodesign, Inc.'s operating margin in 2025?
In 2025, Medeon Biodesign, Inc.'s operating margin was -172.26%, compared with -297.87% in 2024.
How has Medeon Biodesign, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Medeon Biodesign, Inc.'s operating margin was highest in 2022 (-163.53%) and lowest in 2021 (-743.77%).
How does Medeon Biodesign, Inc.'s operating margin compare with similar companies?
Medeon Biodesign, Inc.'s operating margin (-144.72%) is lower than that of all 5 similar companies listed above. The highest among them is Keyence Corporation, with 53.84%.